The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 94, May 2018, Pages 156-167

Patrick Schöffski, Agnieszka Wozniak, Michael G. Leahy, Steinar Aamdal, Piotr Rutkowski, Sebastian Bauer, Stephan Richter, Viktor Grünwald, Maria Debiec-Rychter, Raf Sciot, Birgit Geoerger, Sandrine Marréaud, Sandra Collette, Axelle Nzokirantevye,